Marillion Pharmaceuticals has announced that the science underlying its core technology was published in the journal "Proceedings of the National Academy of Sciences".
Marillion’s nanoplatform conjugates tumor-homing molecules to naturally occurring nanoparticles responsible for lipid transport throughout the body.
The adapted nanoparticles are able to deliver anti-cancer drugs directly into tumor cells.
The technology was developed by scientists from the University of Pennsylvania who helped found the company and who are co-authors of the scientific study published in the PNAS.
Marillion’s nanoparticles, called conjugated lipoproteins, are less than 25 nm in diameter, 10,000 times smaller than the width of a human hair.
Because of their small size they can pass through blood vessel walls to ferry their cargo of anti-cancer drugs to targeted receptors and directly into the cancer cells, leaving the surrounding healthy tissue unaffected.
"We have shown that we can empty these naturally occurring nanoparticles, fill them with chemotherapeutic and imaging agents and then re-route them away from their natural receptors directly to tumor cells," says Gang Zheng, Ph.D., University of Pennsylvania researcher and Marillion co-founder.
Jerry Glickson, Ph.D. also at the University of Pennsylvania and a co-founder of Marillion, added, "As described in the journal, the targeting entity in this study was folic acid, which binds to specific receptors found on certain types of cancers and directs the nanoparticle to the tumor."
"Other targeting entities can also be attached to guide the nanoparticles to alternate tumors or to the tumor vasculature, where agents can be delivered that fight the cancer by literally starving the tumor of its essential blood supply."
"The particles’ trajectory through the body can also be tracked by attaching imaging agents to the nanoparticle, providing the potential for an innovative ‘see and treat’ approach to cancer therapy."
Marillion is currently using its nanoparticles to carry the widely used chemotherapeutic drug paclitaxel into ovarian tumors, and it plans to initiate clinical trials with its first nanoplatform-based drugs within the next two years.
"Our natural nanoparticles can be designed to act as miniature drug-laden missiles that are small enough to target tumor cells, yet are expected to be devoid of immunogenic and other adverse effects on the body," said Zahed Subhan, Ph.D., J.D., CEO of Marillion.
"The results reported in PNAS bode well for the development of our practical nanoparticle-based approach to improving treatment and outcomes for many cancer patients."
The article titled "Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents" initially appeared in the PNAS on-line edition on November 23, 2005.